title: Reply to "Clinical impact and cost of laboratory monitoring need review even in resource-rich setting".
authors.forename: Gary
authors.initials: G
authors.lastname: Fernandez
authors.forename: Samuel
authors.initials: S
authors.lastname: Harris
authors.forename: Maria
authors.initials: M
authors.lastname: Frontini
authors.forename: Rebecca A
authors.initials: RA
authors.lastname: Clark
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D019411:Clinical Laboratory Techniques / Q000191:economics* / Q000379:methods*; D016903:Drug Monitoring / Q000191:economics* / Q000379:methods*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male
chemical_list: D019380:Anti-HIV Agents